1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
The first 2 authors contributed equally to this work.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection
Article first published online: 23 JUN 2009
DOI: 10.1002/cncr.24494
Copyright © 2009 American Cancer Society
Additional Information
How to Cite
Wang, X.-M., Yang, L.-Y., Guo, L., Fan, C. and Wu, F. (2009), p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer, 115: 4554–4563. doi: 10.1002/cncr.24494
Publication History
- Issue published online: 17 SEP 2009
- Article first published online: 23 JUN 2009
- Manuscript Revised: 12 FEB 2009
- Manuscript Accepted: 12 FEB 2009
- Manuscript Received: 30 SEP 2008
Funded by
- National Key Technology R&D Program of China. Grant Numbers: 2001BA703B04, 2004BA703B02
- National Basic Research Program of China. Grant Number: 2004CB720303
- National Natural Science Foundation for Distinguished Young Scholars of China. Grant Number: 30328028
- National High Technology Research and Development Program of China. Grant Number: 2006AA02Z4B2
References
- 1, , , et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.Direct Link:
- 2, , , et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer. 2004; 90: 2349-2355.
- 3, , , et al. Hepatocellular carcinoma cells containing hepatitis B virus X protein have enhanced invasive potential conditionally. Dig Liv Dis. 2006; 38: 262-267.
- 4, , , et al. Progress in surgical treatment of hepatocellular carcinoma. Oncology. 2002; 62( suppl 1): 74-81.
- 5. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2006; 22: 248-253.
- 6. Hepatocellular carcinoma. Curr Opin Gastroenterol. 2005; 21: 308-312.
- 7, , , et al. Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008; 15: 962-971.
- 8, , , et al. Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg. 2008; 12: 327-337.
- 9, , , et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 2007; 46: 446-455.Direct Link:
- 10, , , et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis. 2007; 39: 167-172.
- 11, , , et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 2004; 24: 21-28.Direct Link:
- 12, . The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 2004; 40: 2217-2229.
- 13, , , et al. Proteomics of proteasome complexes and ubiquitinated proteins. Expert Rev Proteomics. 2007; 4: 649-665.
- 14, . Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008; 14: 1649-1657.
- 15. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther. 2003; 2: 623-629.
- 16. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003; 9: 6316-6325.
- 17, , , et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617.
- 18
- 19, , . The proteasome: a worthwhile target for the treatment of solid tumors? Eur J Cancer. 2007; 43: 1125-1133.
- 20, , , et al. PIRH2, A p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003; 112: 779-791.
- 21, , , et al. Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J Mol Endocrinol. 2002; 29: 41-60.
- 22, , . The p53 paddy wagon: COP1, PIRH2 and MDM2 are found resisting apoptosis and growth arrest. Cancer Biol Ther. 2004; 3: 721-725.
- 23, . p53 Ubiquitination: Mdm2 and beyond. Mol Cell. 2006; 21: 307-315.
- 24, , , et al. Expression of PIRH2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst. 2004; 96: 1718-1721.
- 25, , , et al. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol. 2006; 26: 6502-6510.
- 26, , , et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007; 245: 909-922.
- 27, , , et al. Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2006; 12: 5673-5679.
- 28, , , et al. Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma. Cancer. 2008; 112: 2002-2010.Direct Link:
- 29. p53 From pathway to therapy. Carcinogenesis. 2004; 25: 1077-1081.
- 30, , . The P53 pathway: what questions remain to be explored? Cell Death Differ. 2006; 13: 1027-1036.
- 31. Wild-type p53: tumors can't stand it. Cell. 2007; 128: 837-840.
- 32, . Living with p53, dying of p53. Cell. 2007; 130: 597-600.
- 33, , , et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006; 444: 61-66.
- 34, , , et al. p53-Mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science. 2006; 313: 968-971.
- 35, . The p53 pathway: positive and negative feedback loops. Oncogene. 2005; 24: 2899-2908.
- 36. The ubiquitin ligase COP1 is a critical negative regulator of pP53. Nature. 2004; 429: 86-92.
- 37, , . Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase “Synoviolin.” EMBO J. 2007; 26: 113-122.
- 38, , , et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg. 2006; 192: 29-33.
- 39, , , et al. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis. 2007; 25329-25333.
- 40, , , et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 2008; 97: 246-252.Direct Link:
- 41, , , et al. Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma-results of 152 resected cases. Hepatogastroenterology. 2007; 54: 2084-2087.